Lupin launches cream in US to treat skin inflammation
NEW DELHI: Drug firm Lupin has launched in the American market its Clobetasol Propionate topical solution used for providing relief in various skin conditions of the scalp.
The company has launched its Clobetasol Propionate topical solution USP, 0.05 per cent after having received an approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic version of Fougera Pharmaceuticals' Temovate (clobetasol propionate) scalp application, 0.05 per cent, it added.
As per IMS MAT December 2016 data "Temovate clobetasol propionate scalp application had US sales of $64.1 million", Lupin said.
The product is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, it added.
Lupin Ltd stock closed at Rs 1,469.45, down 0.20 per cent, on BSE.
The company has launched its Clobetasol Propionate topical solution USP, 0.05 per cent after having received an approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic version of Fougera Pharmaceuticals' Temovate (clobetasol propionate) scalp application, 0.05 per cent, it added.
As per IMS MAT December 2016 data "Temovate clobetasol propionate scalp application had US sales of $64.1 million", Lupin said.
The product is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, it added.
Lupin Ltd stock closed at Rs 1,469.45, down 0.20 per cent, on BSE.
